Treatment of Acute Lymphoblastic Leukemia in Children

PHASE3CompletedINTERVENTIONAL
Enrollment

800

Participants

Timeline

Start Date

April 30, 2005

Primary Completion Date

August 31, 2014

Study Completion Date

June 30, 2019

Conditions
Drug/Agent Toxicity by Tissue/OrganLeukemia
Interventions
DRUG

asparaginase

DRUG

cyclophosphamide

DRUG

cytarabine

DRUG

dexamethasone

DRUG

dexrazoxane hydrochloride

DRUG

doxorubicin hydrochloride

DRUG

etoposide

Given IV

DRUG

leucovorin calcium

DRUG

mercaptopurine

Given orally

DRUG

methotrexate

DRUG

methylprednisolone

DRUG

pegaspargase

Given IV

DRUG

prednisolone

DRUG

therapeutic hydrocortisone

DRUG

vincristine sulfate

RADIATION

radiation therapy

Trial Locations (8)

10032

Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, New York

10461

Albert Einstein Cancer Center at Albert Einstein College of Medicine, The Bronx

14642

James P. Wilmot Cancer Center at University of Rochester Medical Center, Rochester

02115

Dana Farber Cancer Institute, Boston

02903

Hasbro Children's Hospital, Providence

L8N 3Z5

McMaster Children's Hospital at Hamilton Health Sciences, Hamilton

H3T 1C5

Hopital Sainte Justine, Montreal

GIV 4G2

Centre de Recherche du Centre Hospitalier de l'Universite Laval, Sainte-Foy

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Dana-Farber Cancer Institute

OTHER

NCT00400946 - Treatment of Acute Lymphoblastic Leukemia in Children | Biotech Hunter | Biotech Hunter